VivoSeq
Other

Hallucinations

5

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Hallucinations is an early-stage landscape with 5 programs across 2 companies. The most active players are Novartis, Johnson & Johnson. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

25/100

Attrition Rate

43/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

ApprovedJohnson & Johnson logo

Johnson & Johnson

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Terminated2 · 29%
Completed1 · 14%
Withdrawn1 · 14%
Recruiting1 · 14%
Unknown status1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Toward a Computationally-Informed, Personalized Treatment for Hallucinations
Recruiting·YYale University·Phase 1·NCT04366518·35 enrolled
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
Active, not recruiting·UUniversity College, London·Phase 2·NCT04167813·168 enrolled
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
Completed·—·N/A·NCT05039489·200 enrolled
Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease
Terminated·AAmsterdam UMC, location VUmc·Phase 4·NCT01856738·91 enrolled
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00287742·33 enrolled
Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia
Withdrawn·NNorthwell Health·N/A·NCT02661347
Apomorphine in Parkinson's Disease Patients With Visual Hallucinations
Unknown status·UUniversity Medical Center Groningen·Phase 2·NCT02702076·35 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)